Why Viking Therapeutics Stock Skyrocketed on Tuesday
Yahoo Finance ·
Shares of Viking Therapeutics ( VKTX +35.67% ) surged on Tuesday after the biopharmaceutical specialist announced encouraging clinical trial results for its experimental weight loss drug. People receiving weekly doses of Viking's investigational obesity drug, VK2735, lost 16% to 19% of their bodyweight after 21 weeks, compared with roughly 0% for placebo. Moreover, participants' weight loss was progressive, with no evidence of plateau, suggesting that further weight loss is likely with longer-term dosing.
DYAX Investor Sentiment
Bullish (Long) 47% · Bearish (Short) 53%
437 participants
Related News
- SpaceX's First 100 Days Are in the Books. Here's the Report Card.
- “The New Clippy”: Benioff Uses Salesforce’s Biggest Product Launch in Years to Challenge Microsoft
- Chinese authorities are examining the use of Broadcom’s (AVGO) hardware in state-backed data centres amid efforts to boost domestic producers and cut reliance on foreign AI infrastructure, according to FT
- Shopify (SHOP) Could Be 30% Below Fair Value On Meta Muse Checkout News
- Pat Gelsinger Just Backed a $100 Million Challenge to Nvidia’s AI Networking Moat. AMD Could Benefit
- Intel (INTC) Could Get a Fresh Valuation for Altera. AMD (AMD) Is the Rival to Watch
